Bibliographic Reference
Greaves, M., & Maley, C. C. (2012). Clonal evolution in cancer. Nature, 481(7381), 306–313. https://doi.org/10.1038/nature10762
Core Argument
Cancers evolve by a reiterative process of clonal expansion, genetic diversification, and clonal selection within the adaptive landscapes of tissue ecosystems. Therapeutic intervention can destroy cancer clones and erode their habitats, but it also provides potent selective pressure for the expansion of resistant variants. The inherently Darwinian character of cancer is the primary reason for therapeutic failure, but it may also hold the key to more effective control.
Methods
This is a comprehensive review synthesizing evidence from cancer genomics, evolutionary biology, mathematical modeling (population genetics models by Bozic et al., spatial models by Anderson et al.), single-cell genetic analysis (Navin et al. 2011, Anderson et al. 2011), and xenograft studies. It bridges evolutionary biology tools (coalescent theory, population genetics) with cancer biology observations from whole-genome sequencing, multi-region sampling, and longitudinal studies.
Key Findings
- Modern cancer genomics has validated Nowell’s 1976 model: cancer is a complex Darwinian adaptive system with branching clonal architectures.
- Driver mutations provide an average fitness advantage of only ~0.4% (Bozic et al. 2010 estimate from glioblastoma and pancreatic cancer data) — selection can be very weak.
- Clonal evolution is not always successive selective sweeps; clonal interference (competition between clones) and parallel clonal expansions are likely common given the large population sizes and high mutation rates.
- Subclonal genetic diversity is a robust biomarker for predicting progression to malignancy (demonstrated in Barrett’s esophagus).
- Cancer stem cells are the units of selection — they vary in frequency and phenotype over time, are genetically diverse, and their adaptability is a key reason for therapeutic failure.
- Alternative therapeutic strategies proposed: (i) “ecological therapy” targeting micro-environmental habitats, (ii) adaptive therapy (cytostatic rather than cytotoxic, maintaining stable tumor size rather than eradication), (iii) prevention and early detection before genetic diversification becomes extensive.
Concepts Introduced or Used
clonal-evolution, clonal-expansion, driver-mutation, passenger-mutation, mutator-phenotype, genetic-instability, clonal-interference, selective-sweep, branching-evolution, clonal-heterogeneity, cancer-stem-cell, tissue-ecosystem, adaptive-landscape, therapy-resistance, ecological-therapy, adaptive-therapy, punctuated-equilibrium, chromothripsis, clonal-architecture, hitchhiker-mutation, neutral-evolution, molecular-clock
Entities Referenced
- BCR-ABL (CML), EGFR, KRAS, TP53, MET, TMPRSS2-ERG, PTEN, ABL1, BRAF
- Imatinib, carboplatin
- TRACERx (referenced in principle)
- Nature (journal), whole-genome sequencing, single-cell sequencing
- PyClone, ABSOLUTE (computational tools mentioned conceptually)
Limitations
- Subclonal genetic diversity data is limited to a few studies (Navin et al. 2011 breast cancers, Anderson et al. 2011 ALL) at the time of writing.
- Single-cell genomic interrogation of cancer stem cells was not yet possible in 2012.
- The dynamics of clonal diversification and selection are still “unclear” and require more longitudinal clinical data.
- Adaptive therapy (Gatenby’s OVCAR-3 model) is demonstrated only in xenograft models — clinical translation remains hypothetical.
Relevance to Clonal Evolution
This is the definitive 35-year retrospective on Nowell 1976, updating clonal evolution theory with the genomic era’s findings. It formalizes cancer as a Darwinian system, introduces the clinical implications of subclonal architecture, and proposes evolution-aware therapeutic strategies. Nearly every subsequent paper on cancer evolution directly builds on this framework.